Skip to main content

MBX Biosciences

MBX Biosciences Inc is an American clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. The company utilizes its proprietary Precision Endocrine Peptide (PEP) platform to engineer long-acting peptide candidates for conditions like hypoparathyroidism and post-bariatric hypoglycemia. Principal revenue is currently driven through development capital raised, research collaboration agreements, and milestone payments ahead of commercial authorization. Core end markets encompass endocrinology specialty clinics, rare disease institutes, and prescription patients in North America and international markets. MBX Biosciences holds an innovative position in the biopharmaceutical sector for targeted long-acting peptide drug engineering. The company is headquartered in Carmel, Indiana, and its common stock trades on the Nasdaq Global Market.

4 of the funds FundTelligence covers report a position in MBX Biosciences.

Legal name
MBX Biosciences Inc
Sector
Health Care
Country
United States
Funds holding it
4

Funds holding MBX Biosciences

Loading...